RE:RE:Why is there little market confidence in Biovaxys?IMO in order to see real movement in Biovaxys, they need to generate cash thru something other than a private placement. As the last extended private placement halted early, this appears to be imminent.
Potential Sources of funds:
1). Partnership talks with a Shanghai based pharma (Betta?) are in the works per Passin interviews/newsletter likely MVP-S Phase 3s - lymphoma & Ovarian
2) BARDA (Anthrax)
3). Licensing deal on any DPX application in cancer, infectious disease....
4). Nova Scotia govt funding to "revive IMV" in their community
5). mRNA cancer vax licensing generated thru December Boston Cancer Summit & any associated publications released
CEO Passin, a former investment banker, has pursued various deals/partnerships with Biovaxys, only to terminate to focus on DPX or other ventures. To get the movement everyone wants to see, revenue is needed.
Something like these comparables would be nice,:
https://www.fiercebiotech.com/research/repair-licenses-genevants-nucleic-acid-delivery-tech-107m-bring-therapeutic-mrna
https://www.fiercebiotech.com/biotech/novo-nordisk-bets-600m-biobucks-nanovations-ability-take-genetic-medicines-beyond-liver-0